Conference on Translational Medicine in Autoimmunity

描述（由申请人提供）：最近对自身免疫性疾病基本机制的理解取得了进展，导致了可能干扰疾病过程和限制疾病进展的试剂的开发。尽管免疫介导疗法已被证明对某些自身免疫性疾病有效，但临床免疫学的最新发展将导致治疗自身免疫性疾病的新方法。这些新型药物在治疗人类疾病方面的应用正在扩大。临床和基础科学家熟悉这些治疗这些难治性疾病的新方法是至关重要的。本次会议将重点讨论这些疗法在多种自身免疫性疾病的治疗和管理中的机制和应用，包括多发性硬化症、炎症性肠病、糖尿病、系统性狼疮和类风湿性关节炎。会议的主要重点将是向听众提供信息，以便更好地了解最新技术及其对床边医学的转化。为此，本次会议的主要目标受众将是临床医生，转化研究科学家，博士后研究员和研究生，他们有兴趣收集更多关于该领域当前研究活动的知识。这次会议代表了Keystone专题讨论会的一个重要的新方向。这是对最近制定的“NIH路线图”的回应，该路线图将转化医学作为该地图的关键道路。Keystone专题讨论会与免疫学前沿的历史性联系将使我们能够将基础和临床科学家引入这个新的论坛。

DESCRIPTION (provided by applicant): Recent advances in the understanding of basic mechanisms of autoimmune disease have led to the development of reagents that can potentially interfere with the disease process and limit disease progression. Although immune mediated therapeutics have already been proven effective for selected autoimmune conditions there are recent developments in clinical immunology that will lead to new approaches for the treatment of autoimmune disease. The implementation of these novel agents into treating human disease is expanding. It is essential that clinical and basic scientists become familiar with these novel approaches for the treatment of these refractory conditions. This meeting will focus on the mechanism and utilization of these therapeutics for the treatment and management of several autoimmune diseases including multiple sclerosis, inflammatory bowel disease, diabetes, systemic lupus and rheumatoid arthritis. The primary emphasis for the sessions will be to provide the audience with information to better appreciate the state of the art and its translation to bedside medicine. To this end, the prime target audience for this meeting will be clinical physicians, translational research scientists, post-doctoral fellows and graduate students interested in gathering more knowledge of the current investigational activities in the field. This meeting represents an important new direction for the Keystone Symposia. It is responsive to the recently formulated "NIH Roadmap" that has targeted translational medicine as a key roadway of this map. The historic association of the Keystone Symposia with frontiers in immunology will allow us to bring in both basic and clinical scientists to this new forum.